RELEASE ARCHIVE
Lipum’s final report for Horizon 2020 has been approved
Press release: Umeå, 18 March 2021. Lipum's final report for the EU's Horizon 2020 framework program has been approved and the company will receive 496,000 EUR as final payment from [...]
Kommuniké från årsstämma
Pressmeddelande: Årsstämma i Lipum AB (publ), org.nr 556813-5999 (”Bolaget”) hölls den 17 mars 2021 i Umeå. Genom förhandspoströstning varvid aktieägarna, i enlighet med kallelsens förslag, i huvudsak fattade följande beslut. [...]
Kallelse till årsstämma
Pressmeddelande: Umeå, 4 Mars 2021. Kallelse till Kallelse till årsstämma i Lipum AB. Aktieägarna i Lipum AB, org.nr 556813-5999, kallas härmed till årsstämma den 17 mars 2021. Som en försiktighetsåtgärd [...]
Biologics are a success factor according to Lipum
News: Umeå, 23 February 2021. Article in Biostock Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is [...]
Lipum gives presentation at Aktiespararna
Lipum is presented at Aktiedagen arranged by Aktiespararna in Lund. (Presentation in Swedish)
Lipum planerar notering vid Nasdaq First North
Pressmeddelande: Umeå, 28 januari, 2021. Lipum AB med säte i Umeå grundades år 2010. Nu förbereds kapitalanskaffning genom en notering förutsatt godkänd ansökan vid Nasdaq First North Growth Market under [...]
Marina Norberg new CFO at Lipum
Press release: Umeå, January 26, 2020. Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO). Marina Norberg has extensive experience as an approved auditor at PwC and as authorized [...]
Lipum to carry out an IPO during 2021
News: Umeå, 19 January 2021. Article in Biostock Currently Lipum is planning an IPO (Initial Public Offering) to finance the start of the clinical trials required to take SOL-116 all [...]
Kommuniké från extra bolagsstämma
Pressmeddelande: Extra bolagsstämma i Lipum AB hölls i Umeå den 29 december 2020. […]
Kallelse till extra bolagsstämma för ändring till publikt aktibolag
Pressmeddelande: Umeå, 15 December 2020. Kallelse till extra bolagsstämma i Lipum AB för ändring till publikt aktiebolag. Aktieägarna i Lipum AB, org.nr 556813-5999, kallas härmed till extra bolagsstämma tisdagen den [...]
WE WISH YOU A JOYFUL LUCIA
We wish you a joyful Lucia! From all of us at Lipum
ARTICLE IN THE MAGAZINE “SKELETT OCH LEDHÄLSA”
In the magazine "Skelett och ledhälsa” our founders Professor Olle Hernell, Dr. Susanne Lindquist and Professor Lennart Lundberg were interviewed about our drug candidate SOL-116. SOL-116 is the antibody that [...]
PRESENTATION OF LIPUMS RECENT PROGRESS
At Biostock Life Science Summit last week our CEO Einar Pontén presented the recent progress in bringing our lead candidate SOL-116 towards clinical verification. He also briefly [...]
Digital Resi – Three day conference
Lipum will participate at Digital RESI (Redefining Early Stage Investments), a dedicated global partnering event. The challenge for the attendees will be the geographic time zone issues and that may [...]
Biostock Life Science Summit
Our CEO Einar Pontén is preparing for BioStock Life Science Summit on 17 November at 12:30. He will present our unique approach to treat chronic inflammations and the progress with [...]
Norrlandsfonden invests in lipum
Susanne Lindquist and Olle Hernell, two of Lipums founders. - Lipum is a very exciting company in drug development that also has a strong sustainability perspective, says Anna Hedström, Norrlandsfonden, [...]
Next wave in Immune Therapeutics
On 29-30 September 2020, our CEO Einar Pontén together with Professor Olle Hernell will attend the virtual event by Johnson & Johnson Innovation, in collaboration with Janssen Immunology. Johnson & [...]
Research engineer is strengthen our team
- It´s going to be both fun and exciting to contribute to Lipum's progress, says Assar Bäckman, research engineer. Assar comes with extensive experience in the field of gene expression [...]
Shareholders meeting in Lipum
News: Umeå, 18 August 2020. Lipum invites to a meeting with the shareholders On August 27, Lipum shareholders will meet virtually. The recent progress and plans for the future will [...]
KALLELSE TILL EXTRA BOLAGSSTÄMMA
Pressmeddelande: Umeå, 17 August 2020. Kallelse till extra bolagsstämma Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till extra bolagsstämma fredagen den 28 augusti 2020, kl. 12:00 på [...]
Lipum prepares for LSX Nordic Virtual event
News: Umeå, 13 August 2020. Lipum participate in LSX Nordic Viritual event 1-4 September. LSX is a community of senior life science decision makers where they connect senior life science [...]
Growing up with Juvenile Idiopathic Arthritis
Clara Laurell. Foto: Roger Larsson, Hallandsposten News: Umeå, 27 August 2020. Growing up with Juvenile Idiopathic Arthritis Every year, more than 200 Swedish children are diagnosed with Juvenile Idiopathic Arthritis [...]
The founders want to improve patients’ quality of life
Lipum is on a steady course towards clinical studies with its candidate for the treatment of juvenile idiopathic arthritis (SOL116). Previous we announced that the cell line was fully developed [...]
Capital raise secures development of Lipum’s novel drug
Press release June 25, 2020 Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological [...]
Lipum kallar till årsstämma
Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 16:00 på Tvistevägen 48C i Umeå. Aktieägare som önskar delta i stämman [...]
Another step towards a novel treatment
What effect has elevated levels of our target molecule on human blood? Together with our partner Immuneed we will increase our understanding. Another step towards a novel treatment of inflammatory diseases.
Immuneed announce the start of a new cooperation with Lipum
Immuneed is announceing the start of a our cooperation. Behind our project are extensive discussions and planning, which Dr. Pernilla Abrahamsson, Chief Operating Officer at Lipum sees as a cornerstone [...]
The production development at Abzena proceeds successfully
At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have [...]
Lipum strengthens Board with experienced docent
At the end of last year, we were able to announce that the cell line had been completed. Recently, another good news was brought, a significant reinforcement to the company's [...]
SwedenBIO opens a Q&A function
SwedenBIO has opened up a Q&A function on their website. Here, questions can be asked about the Swedish life science industry's role in meeting current challenges. Click here to get to [...]
Dr Kristian Sandberg new board member of Lipum
Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various [...]
Lipum will attend Bio-Europe Spring 2020
In March Lipum will attend Bio-Europe Spring, Europe's largest partnership conference for the biotechnology industry. Meet us there! Visit site: https://informaconnect.com/bioeurope-spring/
Dr Kristian Sandberg suggested as new board member
Press release Februari 18, 2020 The board of directors of Lipum AB has suggested Dr Kristian Sandberg to be elected as new member of the board at an extraordinary general [...]
Lipum kallar till extra bolagsstämma
Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg [...]
A milestone has been reached
After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and [...]
Professor Anders Fasth joins the scientific advisory board
Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that [...]
Pharma Outsourcing 2019
“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]
Lipum in preparation for Bio-Europe
– Our goal is to meet with investors interested in our next financing round, says our CEO Einar Ponten in preparation for Bio-Europe in Hamburg, 11-13 November. […]
BioStock Life Science Summit
Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]
Lipum participates in investment and partnering meeting
Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019. The goal of the conference is to establish new contacts and identify business [...]
Lipum to Basel for one-to-one meetings
- We are looking forward to one-to-one meetings in Basel, among the largest biopharma hubs in Europe, says CEO Einar Pontén when Lipum is preparing to participate at the 19th [...]
Lipum attends the largest Nordic Partnering Conference
- This is the right arena for Lipum, says Einar Pontén. It gives us an opportunity to meet people and inform about our progress and long-term plan. Lipum will participate [...]
BioStock’s article series on autoimmune disease: Drug development for RA and MS
Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies [...]
Lipum presents at Biostock Live
On August 27, Lipums CEO Einar Pontén will present our recent progress towards a novel treatment of chronic inflammatory diseases. The presentation will be broadcasted live on the web from [...]
Lipum invites to shareholders meeting
On August 28, Lipum shareholders will meet at Clarion Hotel Arlanda Airport. The recent progress and plans for the future will be presented and discussed. More detailed information will be [...]
A valuable and engaged support
We are grateful for the valuable and engaged support from our Umeå Biotech Incubator coach Anne-Charlotte Aronsson. After three years with us she is now moving on and we hope [...]
Kallelse till årsstämma i Lipum AB
Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]
Getting roasted by investors
As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business [...]
Welcome to Lipum, Pernilla!
Name: Pernilla Abrahamsson Education: PhD in medicine Age: 46 Family: Married, two teenagers Hobbies: We spend a lot of time in the cottage and the whole family goes [...]
Pernilla Abrahamsson joins as Chief Operating Officer
Press release may 7, 2019 ”Lipum is a very interesting company in an exciting development. Soon in the clinical phase and I am looking forward to all challenges ahead of [...]
Umeå life science company attends world congress –
“Our product has huge potential”
Press release April 23, 2019 Umeå life science company Lipum will participate in one of the world's largest congresses for rheumatic diseases this June. “The elite of our industry gathers [...]
Lipum attracts interest from life science leaders
Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and [...]
Lipum and Abzena sign integrated CMC agreement
Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a [...]
Umeåföretag tar nästa steg mot ett nytt läkemedel
Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier [...]
Lipum to NASDAQ
On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for [...]
New share issue round about to close on Sunday 17 February
Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical [...]
Lipum at Biostock Live – among listed companies
At this event we will present the progress of our unique and EU Horizon 2020 supported approach for treatment of chronic inflammatory diseases. In addition, it will also be an [...]
Exclusive partnering with nordic life science startups
Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward [...]
There are plenty of opportunities in crowded immunology markets
According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded. Jennifer Taubert, executive vice president and worldwide pharma chairman recently [...]
Lipum on the list of Swedish startups who receive millions from the EU
"Sweden is number eight on the list of European countries that receive the most money" says Johan Lindberg at Vinnova, who helps Swedish companies to apply for EU grants. So [...]
Lipum makes a share issue for faster progress
Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic [...]
Lipum – towards production of its lead candidate
A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe [...]
“Investors are interested” – interview with CEO Einar Pontén
An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets [...]
Biotech Umeå Investment Day 2019
An opportunity for investors on Thursday the 7th of February 2019. An efficient full day of exclusive one-to-one partnering at the Biotech Umeå Investment Day 2019. Book your meeting with [...]
BIO-Europe in Copenhagen, Nov 5-7 2018
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. [...]
Lipum receives 2.2 M€ grant from Horizon 2020
Press release Aug 29, 2018 Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, [...]
Lipum company presentation at Biostock live
Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018. The event is organised by Biostock and will also [...]
Lipum selected as finalist at NLSDays
An international panel of life science investors have selected Lipum as one of 12 companies for the final of the live pitch competition at the Nordic Life Science Days 2018. [...]
Lipum received grant from SWElife
Our project "Validation of a biological candidate drug" has been granted support from SWElife "Projects for better health" program. The competition was fierce so the green tie was used during [...]
Meet Lipum at Biotrinity in London, April 23-25
Learn more about our novel target for treatment of chronic inflammatory diseases at Biotrinity - A Leading Biopartnering and Investment Conference in London, April 23-25, 2018 We will tell you [...]
Invest in Life Science at Grand Hôtel
Biotech Umeå Investment Day 2018 on February 1 at Grand Hôtel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Beside Lipum you can also [...]
Lipum in EMBL Alumni Report 2017
The European Molecular Biology Laboratory (EMBL) was founded more than 40 years ago to be a centre of excellence for Europe’s most talented young scientists in the life sciences. In the Alumni Impact [...]
Horizon 2020 – Seal of Excellence
Seal of Excellence Certificate by European Commission In response to Lipums application ”Novel Target for Treatment of Chronic Inflammatory Diseases” for SME Instrument 2 funding by EU’s Horizon 2020 an international [...]
November, meet us in Berlin and New York
Learn more about our novel target for treatment of chronic inflammatory diseases. We will attend: BIO-Europe in Berlin, Nov 6-8 Nordic-American conference in New York, Nov 13-14 RESI meeting in [...]
BIO-Europe in Berlin Nov 6-8, meet Lipum there.
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our [...]
17th Annual Biotech in Europe Forum
We invite investors to join us in the development towards better treatment of chronic inflammations. Meet us and learn more at the 17th Annual Biotech in Europe Forum, Basel, Sept [...]
Meet Lipum at NLSDays in Malmö, Sept 12-14
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén at [...]
Future medicine for treatment of chronic inflammation
Rheumatism is an autoimmune disease that causes chronic inflammation and pain. The inflammation can break down cartilage, adjacent bones, tendons and arteries. Also eyes and other organs can be affected. About [...]
A novel target and biological drug against chronic inflammatory diseases
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén [...]
Lipum patent granted in Canada
Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred [...]
Lipum presenting at Anglonordic, London, May 31
We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance [...]
Meet Lipum at Bio-Europe Spring 2017
Lipum offer a new route for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Contact us and meet with our CEO Einar Pontén or Chairman [...]
Meet Lipum at the Sachs Associates annual ELSCEO Forum & Exhibition in Zürich
Meet Lipum at Sachs Associates 10th Annual ELSCEO Forum & Exhibition, on 6-7th March 2017 at the Hilton Zürich Airport Hotel, Switzerland. This event bring together a cross-section of venture-funded [...]
Meet Lipum at Biotech Umeå Investment Day 2017 in Stockholm
Biotech Umeå Investment Day 2017 at Grand Hotel in Stockholm is a partnering event, for startups, investors and industrial partners within life science. Please contact us and book a meeting in [...]
Meet Lipum at Swiss Nordic Bio meeting in Zürich
Lipum is actively seeking partners and investors for a faster development of a new biological drug towards an unique target for treatment of autoimmune inflammatory diseases. Swiss Nordic Bio in [...]
Dr Einar Pontén the new CEO at Lipum AB
Press release Dec 29, 2016 The Board of Directors of Lipum AB in Umeå has appointed Dr Einar Pontén new CEO. "We are very pleased to recruit an experienced force [...]